JP5683809B2 - ピロロキノリンキノン依存性可溶性グルコース脱水素酵素の改善された変異体 - Google Patents
ピロロキノリンキノン依存性可溶性グルコース脱水素酵素の改善された変異体 Download PDFInfo
- Publication number
- JP5683809B2 JP5683809B2 JP2009504634A JP2009504634A JP5683809B2 JP 5683809 B2 JP5683809 B2 JP 5683809B2 JP 2009504634 A JP2009504634 A JP 2009504634A JP 2009504634 A JP2009504634 A JP 2009504634A JP 5683809 B2 JP5683809 B2 JP 5683809B2
- Authority
- JP
- Japan
- Prior art keywords
- gdh
- glucose
- mutant
- variant
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000001419 dependent effect Effects 0.000 title claims description 25
- 108040005045 glucose dehydrogenase activity proteins Proteins 0.000 title claims description 8
- MMXZSJMASHPLLR-UHFFFAOYSA-N pyrroloquinoline quinone Chemical compound C12=C(C(O)=O)C=C(C(O)=O)N=C2C(=O)C(=O)C2=C1NC(C(=O)O)=C2 MMXZSJMASHPLLR-UHFFFAOYSA-N 0.000 title description 52
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 136
- 239000008103 glucose Substances 0.000 claims description 136
- 235000001014 amino acid Nutrition 0.000 claims description 80
- 238000006467 substitution reaction Methods 0.000 claims description 70
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 56
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 51
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 51
- 239000000758 substrate Substances 0.000 claims description 51
- 230000035772 mutation Effects 0.000 claims description 47
- 150000001413 amino acids Chemical group 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 35
- 241000588624 Acinetobacter calcoaceticus Species 0.000 claims description 34
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 33
- 239000004471 Glycine Substances 0.000 claims description 30
- 239000013604 expression vector Substances 0.000 claims description 28
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 23
- 239000004473 Threonine Substances 0.000 claims description 23
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 22
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 21
- 235000004279 alanine Nutrition 0.000 claims description 21
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 20
- 238000003780 insertion Methods 0.000 claims description 18
- 230000037431 insertion Effects 0.000 claims description 18
- 238000005259 measurement Methods 0.000 claims description 16
- 101000806049 Acinetobacter calcoaceticus Quinoprotein glucose dehydrogenase B Proteins 0.000 claims description 13
- 108091033319 polynucleotide Proteins 0.000 claims description 11
- 102000040430 polynucleotide Human genes 0.000 claims description 11
- 239000002157 polynucleotide Substances 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- 238000012360 testing method Methods 0.000 claims description 6
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims description 6
- 102220474575 Ubiquitin-conjugating enzyme E2 D1_D87R_mutation Human genes 0.000 claims description 5
- 230000001737 promoting effect Effects 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 238000010647 peptide synthesis reaction Methods 0.000 claims description 3
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 229910052727 yttrium Inorganic materials 0.000 claims description 2
- 230000000694 effects Effects 0.000 description 51
- 125000003275 alpha amino acid group Chemical group 0.000 description 49
- 229940024606 amino acid Drugs 0.000 description 42
- 102000004190 Enzymes Human genes 0.000 description 30
- 108090000790 Enzymes Proteins 0.000 description 30
- 229940088598 enzyme Drugs 0.000 description 30
- 229960002449 glycine Drugs 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 27
- 108090000623 proteins and genes Proteins 0.000 description 23
- 108010050375 Glucose 1-Dehydrogenase Proteins 0.000 description 22
- 229960002898 threonine Drugs 0.000 description 22
- 235000008521 threonine Nutrition 0.000 description 22
- 229960001153 serine Drugs 0.000 description 21
- 235000004400 serine Nutrition 0.000 description 21
- 229960003767 alanine Drugs 0.000 description 20
- 108091028043 Nucleic acid sequence Proteins 0.000 description 16
- 230000006872 improvement Effects 0.000 description 14
- 239000000523 sample Substances 0.000 description 14
- 235000000346 sugar Nutrition 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 150000003588 threonines Chemical group 0.000 description 12
- 239000013612 plasmid Substances 0.000 description 11
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 241000589291 Acinetobacter Species 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 230000009260 cross reactivity Effects 0.000 description 8
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 108020004705 Codon Proteins 0.000 description 6
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 6
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- 229960003136 leucine Drugs 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 150000008163 sugars Chemical class 0.000 description 6
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 5
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 5
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 5
- 229960001230 asparagine Drugs 0.000 description 5
- 235000009582 asparagine Nutrition 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 238000002703 mutagenesis Methods 0.000 description 5
- 231100000350 mutagenesis Toxicity 0.000 description 5
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 5
- 229960005190 phenylalanine Drugs 0.000 description 5
- 235000008729 phenylalanine Nutrition 0.000 description 5
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 230000035882 stress Effects 0.000 description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
- 229960000723 ampicillin Drugs 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 238000004520 electroporation Methods 0.000 description 4
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 4
- 230000009257 reactivity Effects 0.000 description 4
- 238000002741 site-directed mutagenesis Methods 0.000 description 4
- 229960004441 tyrosine Drugs 0.000 description 4
- 235000002374 tyrosine Nutrition 0.000 description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
- 229960004295 valine Drugs 0.000 description 4
- 239000004474 valine Substances 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 108010015776 Glucose oxidase Proteins 0.000 description 3
- 239000004366 Glucose oxidase Substances 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- FBWADIKARMIWNM-UHFFFAOYSA-N N-3,5-dichloro-4-hydroxyphenyl-1,4-benzoquinone imine Chemical compound C1=C(Cl)C(O)=C(Cl)C=C1N=C1C=CC(=O)C=C1 FBWADIKARMIWNM-UHFFFAOYSA-N 0.000 description 3
- 239000000370 acceptor Substances 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- 229960005261 aspartic acid Drugs 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 229940116332 glucose oxidase Drugs 0.000 description 3
- 235000019420 glucose oxidase Nutrition 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000000411 inducer Substances 0.000 description 3
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 210000001322 periplasm Anatomy 0.000 description 3
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- 244000034356 Aframomum angustifolium Species 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 108020004491 Antisense DNA Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 241001646716 Escherichia coli K-12 Species 0.000 description 2
- 108010035289 Glucose Dehydrogenases Proteins 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 241000881812 Kluyvera intermedia Species 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 102000008300 Mutant Proteins Human genes 0.000 description 2
- 108010021466 Mutant Proteins Proteins 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- -1 Q1 and Q2 Chemical class 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 108091081021 Sense strand Proteins 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000003816 antisense DNA Substances 0.000 description 2
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000006356 dehydrogenation reaction Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 235000004554 glutamine Nutrition 0.000 description 2
- 229960002743 glutamine Drugs 0.000 description 2
- 230000008642 heat stress Effects 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000008057 potassium phosphate buffer Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 210000001938 protoplast Anatomy 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 150000004053 quinones Chemical class 0.000 description 2
- 238000002708 random mutagenesis Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 150000003669 ubiquinones Chemical class 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
- RXGJTUSBYWCRBK-UHFFFAOYSA-M 5-methylphenazinium methyl sulfate Chemical compound COS([O-])(=O)=O.C1=CC=C2[N+](C)=C(C=CC=C3)C3=NC2=C1 RXGJTUSBYWCRBK-UHFFFAOYSA-M 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- PHOQVHQSTUBQQK-SQOUGZDYSA-N D-glucono-1,5-lactone Chemical compound OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O PHOQVHQSTUBQQK-SQOUGZDYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 241001131785 Escherichia coli HB101 Species 0.000 description 1
- 102000003983 Flavoproteins Human genes 0.000 description 1
- 108010057573 Flavoproteins Proteins 0.000 description 1
- 108010025076 Holoenzymes Proteins 0.000 description 1
- 229920002177 Icodextrin Polymers 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 101710122864 Major tegument protein Proteins 0.000 description 1
- PYUSHNKNPOHWEZ-YFKPBYRVSA-N N-formyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC=O PYUSHNKNPOHWEZ-YFKPBYRVSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 101710148592 PTS system fructose-like EIIA component Proteins 0.000 description 1
- 101710169713 PTS system fructose-specific EIIA component Proteins 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 101710199973 Tail tube protein Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 101710159648 Uncharacterized protein Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000001323 aldoses Chemical class 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 238000013096 assay test Methods 0.000 description 1
- 238000006701 autoxidation reaction Methods 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 229920001940 conductive polymer Polymers 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 108010011035 endodeoxyribonuclease DpnI Proteins 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 102000054767 gene variant Human genes 0.000 description 1
- 235000012209 glucono delta-lactone Nutrition 0.000 description 1
- 229960003681 gluconolactone Drugs 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 229940016836 icodextrin Drugs 0.000 description 1
- 230000014726 immortalization of host cell Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 125000003071 maltose group Chemical group 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 238000002887 multiple sequence alignment Methods 0.000 description 1
- 229910052762 osmium Inorganic materials 0.000 description 1
- SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 230000037432 silent mutation Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 229940045042 ubiquinone q2 Drugs 0.000 description 1
- SOECUQMRSRVZQQ-UHFFFAOYSA-N ubiquinone-1 Chemical compound COC1=C(OC)C(=O)C(CC=C(C)C)=C(C)C1=O SOECUQMRSRVZQQ-UHFFFAOYSA-N 0.000 description 1
- SQQWBSBBCSFQGC-JLHYYAGUSA-N ubiquinone-2 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CCC=C(C)C)=C(C)C1=O SQQWBSBBCSFQGC-JLHYYAGUSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06007779.9 | 2006-04-13 | ||
| EP06007779 | 2006-04-13 | ||
| PCT/EP2007/003207 WO2007118647A1 (en) | 2006-04-13 | 2007-04-11 | Improved mutants of pyrroloquinoline quinone dependent soluble glucose dehydrogenase |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013130565A Division JP5937547B2 (ja) | 2006-04-13 | 2013-06-21 | ピロロキノリンキノン依存性可溶性グルコース脱水素酵素の改善された変異体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009533033A JP2009533033A (ja) | 2009-09-17 |
| JP2009533033A5 JP2009533033A5 (enExample) | 2010-01-14 |
| JP5683809B2 true JP5683809B2 (ja) | 2015-03-11 |
Family
ID=36579921
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009504634A Active JP5683809B2 (ja) | 2006-04-13 | 2007-04-11 | ピロロキノリンキノン依存性可溶性グルコース脱水素酵素の改善された変異体 |
| JP2013130565A Active JP5937547B2 (ja) | 2006-04-13 | 2013-06-21 | ピロロキノリンキノン依存性可溶性グルコース脱水素酵素の改善された変異体 |
| JP2016022203A Active JP6185617B2 (ja) | 2006-04-13 | 2016-02-08 | ピロロキノリンキノン依存性可溶性グルコース脱水素酵素の改善された変異体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013130565A Active JP5937547B2 (ja) | 2006-04-13 | 2013-06-21 | ピロロキノリンキノン依存性可溶性グルコース脱水素酵素の改善された変異体 |
| JP2016022203A Active JP6185617B2 (ja) | 2006-04-13 | 2016-02-08 | ピロロキノリンキノン依存性可溶性グルコース脱水素酵素の改善された変異体 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7732179B2 (enExample) |
| EP (2) | EP2010649B1 (enExample) |
| JP (3) | JP5683809B2 (enExample) |
| KR (1) | KR101168623B1 (enExample) |
| CN (1) | CN101421396B (enExample) |
| AU (1) | AU2007237478B2 (enExample) |
| BR (1) | BRPI0710131B1 (enExample) |
| CA (1) | CA2649135C (enExample) |
| ES (2) | ES2624805T3 (enExample) |
| HU (2) | HUE049911T2 (enExample) |
| MX (1) | MX2008013001A (enExample) |
| PL (2) | PL3246402T3 (enExample) |
| PT (2) | PT2010649T (enExample) |
| WO (1) | WO2007118647A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5753720B2 (ja) * | 2010-04-22 | 2015-07-22 | アークレイ株式会社 | バイオセンサ |
| US20130092536A1 (en) | 2010-07-23 | 2013-04-18 | Roche Diagnostics Operations, Inc. | Zwitterion buffer containing compositions and uses in electroanalytical methods |
| US20130337485A1 (en) | 2010-12-20 | 2013-12-19 | Lek Pharmaceuticals D.D | Enzymatic synthesis of active pharmaceutical ingredient and intermediates thereof |
| EP2465936A1 (en) | 2010-12-20 | 2012-06-20 | LEK Pharmaceuticals d.d. | Enzymatic synthesis of statins and intermediates thereof |
| EP3901624B1 (en) | 2010-12-22 | 2024-01-31 | Roche Diabetes Care GmbH | Methods to compensate for sources of error during electrochemical testing |
| CN102559624B (zh) * | 2012-03-05 | 2013-10-16 | 浙江德清汇宁生物科技有限公司 | 一种吡咯喹啉醌依赖型葡萄糖脱氢酶的热稳定性突变体及其高通量筛选方法 |
| CA2865678C (en) | 2012-04-19 | 2018-03-13 | Susanne BALDUS | Method and device for determining an analyte concentration in blood |
| EP2811299A1 (en) | 2013-06-07 | 2014-12-10 | Roche Diagniostics GmbH | Test element for detecting at least one analyte in a body fluid |
| JP6998863B2 (ja) | 2015-09-25 | 2022-02-04 | エフ．ホフマン－ラ ロシュ アーゲー | 深共融溶媒におけるソルターゼａを利用したアミド基転移 |
| WO2017050874A1 (en) | 2015-09-25 | 2017-03-30 | F. Hoffmann-La Roche Ag | Process for producing thioesters employing a sortase a |
| CN105331590B (zh) * | 2015-10-29 | 2020-02-28 | 英科隆生物技术（杭州）有限公司 | 葡萄糖特异性改善的可溶性吡咯喹啉醌依赖性葡萄糖脱氢酶突变体、聚核苷酸及其应用 |
| CN111073866B (zh) | 2015-10-29 | 2024-03-19 | 英科隆生物技术（杭州）有限公司 | PQQ-sGDH突变体、聚核苷酸及其在葡萄糖检测中的应用 |
| CN108350439A (zh) | 2015-12-21 | 2018-07-31 | 豪夫迈·罗氏有限公司 | 来自粪产碱菌的突变体3-羟基丁酸脱氢酶及其相关方法和用途 |
| WO2017137491A1 (en) | 2016-02-09 | 2017-08-17 | Roche Diabetes Care Gmbh | Mutant 3-hydroxybutyrate dehydrogenase from rhodobacter sphaeroides as well as methods and uses involving the same |
| PL3523639T3 (pl) | 2016-10-05 | 2025-03-17 | F. Hoffmann-La Roche Ag | Odczynniki wykrywające i układy elektrod do elementów diagnostycznych testów wieloanalitowych oraz sposoby ich zastosowania |
| CN115820608B (zh) * | 2022-08-31 | 2024-06-04 | 中国海洋大学 | λ-卡拉胶酶突变体OUC-CglA-DPQQ及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3716957A1 (de) | 1987-05-20 | 1988-12-01 | Boehringer Mannheim Gmbh | Expressionsvektor zur regulierbaren expression von fremdgenen in prokaryonten |
| DE4311464A1 (de) | 1993-04-08 | 1994-10-13 | Boehringer Mannheim Gmbh | Verfahren zur kolorimetrischen Bestimmung eines Analyten mit einer PQQ-abhängigen Dehydrogenase |
| DE19639169A1 (de) | 1996-09-24 | 1998-04-02 | Boehringer Mannheim Gmbh | Redoxaktive Verbindungen und deren Anwendung |
| JPH10243786A (ja) | 1997-03-03 | 1998-09-14 | Koji Hayade | 改変型グルコース脱水素酵素 |
| US5997817A (en) | 1997-12-05 | 1999-12-07 | Roche Diagnostics Corporation | Electrochemical biosensor test strip |
| JPH11243949A (ja) | 1998-03-03 | 1999-09-14 | Toyobo Co Ltd | Ｐｑｑを補欠分子族とするグルコースデヒドロゲナーゼおよびその製造方法 |
| CA2368461A1 (en) * | 1999-02-19 | 2000-08-24 | Winfried Linxweiler | Glucose dehydrogenase fusion proteins and their utilization in expression systems |
| JP2000350588A (ja) * | 1999-04-08 | 2000-12-19 | Koji Hayade | グルコース脱水素酵素 |
| TWI224136B (en) | 1999-04-30 | 2004-11-21 | Koji Sode | Glucose dehydrogenase |
| JP3845618B2 (ja) * | 2000-10-27 | 2006-11-15 | エフ．ホフマン−ラ ロシュ アーゲー | 可溶性ピロロキノリンキノン−依存性グルコースデヒドロゲナーゼのバリアント |
| JP2004344145A (ja) * | 2002-05-27 | 2004-12-09 | Toyobo Co Ltd | 基質特異性または安定性に優れたピロロキノリンキノン（ｐｑｑ）依存性グルコースデヒドロゲナーゼ改変体 |
| JP2004173538A (ja) * | 2002-11-25 | 2004-06-24 | Amano Enzyme Inc | ピロロキノリンキノン依存性グルコース脱水素酵素 |
| CA2570593C (en) * | 2004-07-20 | 2012-03-20 | F. Hoffmann-La Roche Ag | Genetically engineered pyrroloquinoline quinone dependent glucose dehydrogenase comprising an amino acid insertion |
-
2007
- 2007-04-11 CA CA2649135A patent/CA2649135C/en active Active
- 2007-04-11 BR BRPI0710131-7A patent/BRPI0710131B1/pt active Search and Examination
- 2007-04-11 PT PT77241487T patent/PT2010649T/pt unknown
- 2007-04-11 KR KR1020087025007A patent/KR101168623B1/ko active Active
- 2007-04-11 ES ES07724148.7T patent/ES2624805T3/es active Active
- 2007-04-11 EP EP07724148.7A patent/EP2010649B1/en active Active
- 2007-04-11 ES ES17151869T patent/ES2807530T3/es active Active
- 2007-04-11 HU HUE17151869A patent/HUE049911T2/hu unknown
- 2007-04-11 MX MX2008013001A patent/MX2008013001A/es active IP Right Grant
- 2007-04-11 JP JP2009504634A patent/JP5683809B2/ja active Active
- 2007-04-11 PT PT171518699T patent/PT3246402T/pt unknown
- 2007-04-11 PL PL17151869T patent/PL3246402T3/pl unknown
- 2007-04-11 HU HUE07724148A patent/HUE032804T2/en unknown
- 2007-04-11 EP EP17151869.9A patent/EP3246402B1/en active Active
- 2007-04-11 WO PCT/EP2007/003207 patent/WO2007118647A1/en not_active Ceased
- 2007-04-11 AU AU2007237478A patent/AU2007237478B2/en active Active
- 2007-04-11 CN CN200780013259.8A patent/CN101421396B/zh active Active
- 2007-04-11 PL PL07724148T patent/PL2010649T3/pl unknown
-
2008
- 2008-10-13 US US12/250,241 patent/US7732179B2/en active Active
-
2013
- 2013-06-21 JP JP2013130565A patent/JP5937547B2/ja active Active
-
2016
- 2016-02-08 JP JP2016022203A patent/JP6185617B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3246402A1 (en) | 2017-11-22 |
| PL3246402T3 (pl) | 2020-10-19 |
| BRPI0710131B1 (pt) | 2020-03-10 |
| EP3246402B1 (en) | 2020-05-20 |
| AU2007237478B2 (en) | 2011-05-19 |
| US7732179B2 (en) | 2010-06-08 |
| PL2010649T3 (pl) | 2017-08-31 |
| PT2010649T (pt) | 2017-05-03 |
| HUE049911T2 (hu) | 2020-11-30 |
| ES2807530T3 (es) | 2021-02-23 |
| PT3246402T (pt) | 2020-07-14 |
| ES2624805T3 (es) | 2017-07-17 |
| HUE032804T2 (en) | 2017-11-28 |
| CA2649135A1 (en) | 2007-10-25 |
| MX2008013001A (es) | 2008-10-17 |
| EP2010649A1 (en) | 2009-01-07 |
| AU2007237478A1 (en) | 2007-10-25 |
| JP2016119904A (ja) | 2016-07-07 |
| HK1131633A1 (zh) | 2010-01-29 |
| US20090148874A1 (en) | 2009-06-11 |
| JP6185617B2 (ja) | 2017-08-23 |
| KR101168623B1 (ko) | 2012-08-03 |
| JP2009533033A (ja) | 2009-09-17 |
| CA2649135C (en) | 2013-11-19 |
| CN101421396B (zh) | 2016-01-20 |
| CN101421396A (zh) | 2009-04-29 |
| JP2013198497A (ja) | 2013-10-03 |
| JP5937547B2 (ja) | 2016-06-22 |
| KR20080106349A (ko) | 2008-12-04 |
| EP2010649B1 (en) | 2017-03-08 |
| BRPI0710131A2 (pt) | 2011-08-02 |
| WO2007118647A1 (en) | 2007-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6185617B2 (ja) | ピロロキノリンキノン依存性可溶性グルコース脱水素酵素の改善された変異体 | |
| JP2004512047A (ja) | 可溶性ピロロキノリンキノン−依存性グルコースデヒドロゲナーゼのバリアント | |
| NO340499B1 (no) | Variant av den løselige formen av pyrrolokinolinkinonavhengig glukosedehydrogenase som omfatter én aminosyre insersjon og minst én aminosyre substitusjon, et isolert polynukleotid som koder for varianten, en ekspresjonsvektor som omfatter det isolert polynukleotidet, en vertscelle som omfatter ekspresjonsvektoren, en fremgangsmåte for fremstilling av s-GDH-varianter som omfatter dyrking av vertscellen, en fremgangsmåte for fremstilling av s-GDH-varianter i et cellefritt peptidsyntesesystem, en fremgangsmåte for påvisning, bestemmelse eller måling av glukose i en prøve ved å anvende en variant, samt en innretning for påvisningen eller målingen av glukose i en prøve. | |
| JP4782138B2 (ja) | ピロロキノリンキノン依存性グルコースデヒドロゲナーゼの熱安定性変異体 | |
| HK1131633B (en) | Improved mutants of pyrroloquinoline quinone dependent soluble glucose dehydrogenase | |
| HK1107829B (en) | Genetically engineered pyrroloquinoline quinone dependent glucose dehydrogenase comprising an amino acid insertion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091119 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20091119 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120502 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120802 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130321 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140919 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140925 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20141030 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20141105 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141127 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150114 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5683809 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |